The development of biological agents against tumor necrosis factor (TNF) has revolutionized
the management of inflammatory bowel disease (IBD), frequently achieving induction and …

Immunosuppressive agents have become an established part of the therapeutic
armamentarium for inflammatory bowel disease (IBD). However, when used in transplant …

Introduction: The advent of tumor necrosis factor (TNF) antagonists represented a radical
change in the management of inflammatory bowel disease (IBD). Both in short-and long …

Background The aim of this study was to evaluate the short-and long-term safety experience
of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. Methods The …

The current treatment of Crohn's disease is limited by a lack of long-term efficacy of
corticosteroid therapy and the associated side effects. Biological treatment strategies aimed …

Remarkable advances have been made in the treatment of inflammatory bowel disease
since the introduction of anti‐tumor necrosis factor‐α agents, especially for patients who are …

Background The long‐term outcome of patients after antitumour necrosis factor alpha (anti‐
TNF) discontinuation is not well known. Aims To assess the risk of relapse in the long‐term …

Background The discontinuation of anti‐tumour necrosis factor (anti‐TNF) treatment in
inflammatory bowel disease (IBD) patients in remission could be considered. Aim To …

Inflammatory bowel disease (IBD), most commonly referring to Crohn's disease and
ulcerative colitis, is a chronic and disabling condition with an increasing incidence in …

Inflammatory bowel diseases (IBDs) are chronic conditions of the gastrointestinal tract in
which dysregulated immune responses cause persistent inflammation of the gut mucosa …